Growing Preference for Non – invasive prenatal testing (NIPT) Techniques Over Invasive Methods
How much is the non-invasive prenatal testing (NIPT) market worth?
Maternal age refers to the age of women at the time of delivery. Advancing maternal age can result in a number of health complications, such as decreased fertility, high blood pressure, and an increase in the risk of miscarriage, stillbirths, and maternal death.
The global non-invasive prenatal testing (NIPT) market is estimated to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019, at a CAGR of 13.5% during the forecast period. Growth in this market is driven by the high risk of chromosomal abnormalities with increasing maternal age, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for NIPT, and increasing awareness of NIPT. However, a dearth of skilled professionals is restraining the growth of this market.
The cfDNA in maternal plasma tests segment is expected to grow at the highest CAGR during the forecast period
By method, the NIPT products market is segmented into ultrasound detection, biochemical screening tests, and cell-free DNA in maternal plasma tests. The cfDNA in maternal plasma tests segment is expected to grow at the highest CAGR during the forecast period. The high growth of this segment is attributed to technological advancements and increasing company initiatives to develop new products.
Download PDF Brochure @
The trisomy applications segment accounted for the largest share of the global NIPT market in 2018
Based on application, the non-invasive prenatal testing (NIPT) market is segmented into trisomy, microdeletion syndrome, and other applications (gender identification and the detection of monogenic disorders, Klinefelter syndrome, and Rhesus (Rh) blood type). In 2018, trisomy was the largest application segment of the NIPT market.
Emerging countries such as China, India, Brazil, and Mexico are expected to offer significant growth opportunities to market players in the coming years. The high growth in these markets can majorly be attributed to the improving healthcare infrastructure, increasing public healthcare expenditure, the presence of a large target patient population, and growing awareness and availability of advanced technologies.
Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=145607690
Challenge: Reliability of test results, especially in obese women
NIPT tests can be performed in patients between 10 and 20 weeks of the gestation period. These tests require the extraction of fetal DNA from maternal blood to determine chromosomal abnormalities. The majority of cell-free DNA circulating in maternal blood is of maternal origin, and only 10–15% is of fetal origin.
The major players in the global medical device reprocessing market are The NIPT market is diversified and highly competitive, with a large number of players competing for market space. The prominent players in the market are Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), GE Healthcare (US), BGI (China), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer Inc. (US), Laboratory Corporation of America Holdings (US), Natera, Inc. (US), and Yourgene Health (UK)
Key Questions Addressed by the Report
- Where will all these developments take the industry in the mid to long-term?
- What types of annual and multi-year partnerships are NIPT product and service companies exploring?
- Which are the key players in the market and how intense is the competition?
- Which are the recent contracts and agreements key players have signed?
- What are the recent trends affecting NIPT product and service providers?
Company Name: MarketsandMarkets
Contact Person: Mr. Aashish Mehra
Email: Send Email
Address:630 Dundee Road Suite 430
State: IL 60062
Country: United States